Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.

Saved in:
Bibliographic Details
Title: Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.
Authors: Wu, Chao1 (AUTHOR), Niu, Xuping2 (AUTHOR), Wang, Xiaohua3 (AUTHOR), Su, Juan4 (AUTHOR), Zhao, Hengguang5 (AUTHOR), Lin, Mao6 (AUTHOR), Yang, Chunjun7 (AUTHOR), Qin, Xiaoming8 (AUTHOR), Guo, Shuping9 (AUTHOR), Jiang, Cunhuo10 (AUTHOR), Tang, Hui11 (AUTHOR), Yang, Haijing11 (AUTHOR), Wu, Liming12 (AUTHOR), Zhu, Min13 (AUTHOR), Wei, Aihua14 (AUTHOR), Tao, Xiaohua15 (AUTHOR), Zhang, Yiwen15 (AUTHOR), Shu, Chang1 (AUTHOR), Liu, Jiawei1 (AUTHOR), Yang, Lu1 (AUTHOR)
Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3431-3443. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938210
DOI:10.1007/s13555-026-01787-x